// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

A combination of both testosterone and white blood count as predictive factors of overall survival in localized prostate cancer.

Daniel Taussky - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Androgen Tear

Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy.

Petros Grivas - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Mutations in Influenza A Virus and Clinical Implications in Transplant Recipients.

V. Ferreira - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

N/A

Neutropenia in Kidney and Liver Transplant Recipients: Risk Factors and Consequences.

T. Mavrakanas - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

Efficacy of mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients.

Roger Li - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The use of five-alpha reductase inhibitors and their association with reclassification and pathologic outcomes in the Canary Prostate Active Surveillance Study (PASS).

James T Kearns - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Normothermic Ex-Vivo Kidney Perfusion Improves Function of Extreme Marginal Renal Grafts Subjected to Prolonged Ischemia.

P. Urbanellis - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

tryptophan

Obesity Predicts New-Onset Diabetes After Live Kidney Donation.

K. Lentine - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Objective Assessment of Graft Metabolism and Function During Ex Vivo Liver Perfusion.

J. Echeverri - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Alkaline phosphatase

Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.

Edwin M. Posadas - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Permanent seed brachytherapy for low risk prostate cancer, long term outcome, and urinary toxicity.

Hamid Raziee - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

iodine-125

De novo metastatic prostate cancer: Patterns of PSA testing prediagnosis and disease characteristics.

Yasser Ged - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Effect of enzalutamide on sensitivity in prostate cancer cells to radiation by inhibition of DNA double strand break repair.

Maryam Ghashghaei - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Outcomes of Recurrent Clostridium difficile Infection in Solid Organ Transplant Recipients.

M. Shiotsuka - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

N/A

Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP).

Axel Heidenreich - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Radium-223 Dichloride

Molecular dissection of primary mediastinal germ cell tumors.

Lucia Nappi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Pediatric Recipients of Deceased Adult Donor Kidneys Have Equivalent Outcomes Compared with Pediatric Donors.

D. Mikhail - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

Relationships between an androgen receptor output signature (ARoS), AR expression, and poor prostate cancer prognosis in RP tissues.

Mohammed Alshalalfa - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Androgen Tear

Genomic Classifier to augment the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model.

Firas Abdollah - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Early toxicity in a prospective phase I/II trial of MRI-assisted focal boost integrated with HDR monotherapy for low- and intermediate-risk prostate cancer.

Laura D'alimonte - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved